Exploring Epidermal Growth Factor Receptor (EGFR) Inhibitor Features: The Role of Fused Dioxygenated Rings on the Quinazoline Scaffold
Journal of Medicinal Chemistry2010Vol. 53(4), pp. 1862–1866
Citations Over TimeTop 14% of 2010 papers
Adriana Chilin, Maria Teresa Conconi, Giovanni Marzaro, Adriano Guiotto, Luca Urbani, Francesca Tonus, Pierpaolo Parnigotto
Abstract
A number of dioxolane, dioxane, and dioxepine quinazoline derivatives have been synthetized and evaluated as EGFR inhibitors. Their cytotoxic activity has been tested against two cell lines overexpressing and not expressing EGFR. Most derivatives were able to counteract EGF-induced EGFR phosphorylation, and their potency was comparable to the reference compound PD153035. The size of the fused dioxygenated ring was crucial for the biological activity, the dioxane derivatives being the most promising class of this series.
Related Papers
- → Epidermal Growth Factor Receptor Biology in Head and Neck Cancer(2006)733 cited
- → Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches(2021)15 cited
- → A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors(2008)12 cited
- → Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas1(1993)54 cited
- → Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as PotentialInhibitors of Epidermal Growth Factor Receptor(2022)1 cited